Program
Autologous Tumor-infiltrating Lymphocytes GT307
Its studies are led by Grit Biotechnology.
Drug pageAutologous Tumor-infiltrating Lymphocytes GT307: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Furthest: no phase, since Apr 30, 20244 company-led studies, 3 open or runningNext primary completion: Apr 18, 2027
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grit Biotechnology | 43 open or running | no phasesince Apr 30, 2024 | Apr 30, 2024 | Apr 18, 2027NCT06397963 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 30, 2024First study: no phase study in Solid Tumor, AdultFirst studyNCT06397963 · 18 planned · China
- Jun 7, 2024No phase study in AdultNCT06453057 · 18 planned · China
- Feb 5, 2025No phase study in AdultNCT06819280 · 18 planned · China
- Mar 31, 2026No phase study in Advanced Solid TumorsNCT07534813 · China
Ahead
- Apr 18, 2027Primary completion: no phase study in Solid Tumor, AdultNCT06397963
- May 27, 2027Primary completion: no phase study in AdultNCT06819280
- Jun 6, 2027Primary completion: no phase study in AdultNCT06453057
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07534813Advanced Solid Tumors · China | – | Withdrawn | May 31, 2028 | 0 |
| NCT06819280Adult · China | – | Recruiting | May 27, 2027 | 18 |
| NCT06453057Adult · China | – | Recruiting | Jun 6, 2027 | 18 |
| NCT06397963Solid Tumor, Adult · China | – | Recruiting | Apr 18, 2027 | 18 |
How it is read
Names in the registry
- “GT307 injection”, 4 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.